BACKGROUND: Esophageal remodeling occurs in eosinophilic esophagitis (EE) patients but whether the components of remodeling in the subepithelium are reversible by administration of topical oral corticosteroids is unknown. METHODS: We quantitated the degree of lamina propria remodeling in esophageal biopsies obtained before and after at least 3 months of therapy with budesonide in 16 pediatric EE subjects. In addition, we investigated whether corticosteroid therapy modulated vascular activation (expression of VCAM-1; level of interstitial edema), TGFbeta(1) activation (levels of TGFbeta(1), phosphorylated Smad2/3), and performed a pilot analysis of a polymorphism in the TGFbeta(1) promoter in relation to EE subjects who had reduced remodeling with budesonide therapy. RESULTS: EE subjects were stratified based on the presence (n = 9) or absence (n = 7) of decreased epithelial eosinophilia following budesonide. Patients with residual eosinophil counts of <or=7 eosinophils per high power field in the epithelial space (responders) demonstrated significantly reduced esophageal remodeling with decreased fibrosis, TGFbeta(1) and pSmad2/3 positive cells, and decreased vascular activation in association with budesonide therapy. Responders were more likely to have a CC genotype at the -509 position in the TGFbeta(1) promoter. CONCLUSIONS: Reductions in epithelial eosinophils following budesonide therapy were associated with significantly reduced esophageal remodeling.
BACKGROUND:Esophageal remodeling occurs in eosinophilic esophagitis (EE) patients but whether the components of remodeling in the subepithelium are reversible by administration of topical oral corticosteroids is unknown. METHODS: We quantitated the degree of lamina propria remodeling in esophageal biopsies obtained before and after at least 3 months of therapy with budesonide in 16 pediatric EE subjects. In addition, we investigated whether corticosteroid therapy modulated vascular activation (expression of VCAM-1; level of interstitial edema), TGFbeta(1) activation (levels of TGFbeta(1), phosphorylated Smad2/3), and performed a pilot analysis of a polymorphism in the TGFbeta(1) promoter in relation to EE subjects who had reduced remodeling with budesonide therapy. RESULTS: EE subjects were stratified based on the presence (n = 9) or absence (n = 7) of decreased epithelial eosinophilia following budesonide. Patients with residual eosinophil counts of <or=7 eosinophils per high power field in the epithelial space (responders) demonstrated significantly reduced esophageal remodeling with decreased fibrosis, TGFbeta(1) and pSmad2/3 positive cells, and decreased vascular activation in association with budesonide therapy. Responders were more likely to have a CC genotype at the -509 position in the TGFbeta(1) promoter. CONCLUSIONS: Reductions in epithelial eosinophils following budesonide therapy were associated with significantly reduced esophageal remodeling.
Authors: Eric S Silverman; Lyle J Palmer; Venkat Subramaniam; Arlene Hallock; Sheeba Mathew; Joseph Vallone; Debora S Faffe; Toshiki Shikanai; Benjamin A Raby; Scott T Weiss; Stephanie A Shore Journal: Am J Respir Crit Care Med Date: 2003-11-03 Impact factor: 21.405
Authors: Anil Mishra; Meiqin Wang; Venkatarajani R Pemmaraju; Margaret H Collins; Patricia C Fulkerson; J Pablo Abonia; Carine Blanchard; Philip E Putnam; Marc E Rothenberg Journal: Gastroenterology Date: 2007-10-05 Impact factor: 22.682
Authors: Elizabeth T Schaefer; Joseph F Fitzgerald; Jean P Molleston; Joseph M Croffie; Marian D Pfefferkorn; Mark R Corkins; Joel D Lim; Steven J Steiner; Sandeep K Gupta Journal: Clin Gastroenterol Hepatol Date: 2008-02 Impact factor: 11.382
Authors: Robert C Kapel; Jocelyne K Miller; Carlos Torres; Saime Aksoy; Richard Lash; David A Katzka Journal: Gastroenterology Date: 2008-02-14 Impact factor: 22.682
Authors: Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg Journal: Gastroenterology Date: 2007-08-08 Impact factor: 22.682
Authors: Amir F Kagalwalla; Noorain Akhtar; Samantha A Woodruff; Bryan A Rea; Joanne C Masterson; Vincent Mukkada; Kalyan R Parashette; Jian Du; Sophie Fillon; Cheryl A Protheroe; James J Lee; Katie Amsden; Hector Melin-Aldana; Kelley E Capocelli; Glenn T Furuta; Steven J Ackerman Journal: J Allergy Clin Immunol Date: 2012-04-01 Impact factor: 10.793
Authors: Amanda B Muir; Kara Dods; Steven J Henry; Alain J Benitez; Dale Lee; Kelly A Whelan; Maureen DeMarshall; Daniel A Hammer; Gary Falk; Rebecca G Wells; Jonathan Spergel; Hiroshi Nakagawa; Mei-Lun Wang Journal: J Pediatr Gastroenterol Nutr Date: 2016-08 Impact factor: 2.839